Nam Hoon Kim (Korea University Anam Hospita)

2004, Korea University College of Medicine, MD

2015, Korea University College of Medicine, PhD

2016-Present, Korea University College of Medicine, Korea University Anam Hospital, Professor

Diabetic Kidney Disease, Diabetes therapeutics, Early-onset type 2 diabetes, Lipid Metabolism

Kim JY, Jang HM, Lee HJ, Lee AH, Kim DH, Kim SG, Kim NH. Sodium-glucose cotransporter 2 inhibitor ameliorates thiazolidinedione-induced fluid retention through vascular leakage reduction in white adipose tissue. Diabetes Obes Metab. 2026 Mar;28(3):1764-1777.

Kim JY, Chung SM, Kim NH. Managing dyslipidemia in chronic kidney disease: a comprehensive overview of evidence and recommendations. Korean J Intern Med. 2025 Nov;40(6):876-889.

Kim JY, Lee J, Kim SG, Kim NH. Beta-Cell Function, Insulin Sensitivity, and Metabolic Characteristics in Young-Onset Type 2 Diabetes Mellitus: Findings from Anam Diabetes Observational Study. Diabetes Metab J. 2025 Nov;49(6):1287-1297.

Kim JY, Kim NH, Lee J, Kim DH, Kim SG. Fenofibrate therapy and risk of heart failure outcomes in patients with Type 2 diabetes: a propensity-matched cohort study. Eur Heart J Cardiovasc Pharmacother. 2025 Nov 4;11(7):620-629.

Kim JY, Park S, Park M, Kim NH, Kim SG. Income-Related Disparities in Mortality Among Young Adults With Type 2 Diabetes. JAMA Netw Open. 2024 Nov 4;7(11):e2443918.